Radioiodine treatment of Graves' disease. An assessment of its potential risks

Journal Article · Mon Dec 01 00:00:00 EST 1986 · Ann. Intern. Med.; (United States)

DOI:https://doi.org/10.7326/0003-4819-105-6-900· OSTI ID:6915326

Graham, G D; Burman, K D

Concern about the side effects of radiation exposure has deterred physicians from using radioiodine treatment for Graves' disease, although the efficacy and safety of this treatment have been established in the 35 years since its introduction. In that time, no significant side effects have been discovered. We believe iodine-131 should be considered the treatment of choice in most patients with Graves' disease. This article reviews the current understanding of the risks in radioiodine treatment of Graves' disease, including the risks for teratogenicity, genetic damage, carcinogenesis, and cellular dysfunction.

• Research Organization: Walter Reed Army Medical Center, Washington, DC
• OSTI ID: 6915326
• Journal Information: Ann. Intern. Med.; (United States), Vol. 6, Issue 6
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
HYPERTHYROIDISM
RADIOTHERAPY
EFFICIENCY
IODINE 131
PATIENTS
SIDE EFFECTS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
DAYS LIVING RADIOISOTOPES
DISEASES
ENDOCRINE DISEASES
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
MEDICINE
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
RADIOISOTOPES
RADIOLOGY
THERAPY
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)